These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22689074)

  • 1. Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody.
    Gu L; Ruff LE; Qin Z; Corr M; Hedrick SM; Sailor MJ
    Adv Mater; 2012 Aug; 24(29):3981-7. PubMed ID: 22689074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
    Li F; Ravetch JV
    Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
    Shoji T; Saito R; Chonan M; Shibahara I; Sato A; Kanamori M; Sonoda Y; Kondo T; Ishii N; Tominaga T
    Neuro Oncol; 2016 Aug; 18(8):1120-8. PubMed ID: 26917236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luminescent Porous Silicon Nanoparticles for Continuous Wave and Time-Gated Photoluminescence Imaging.
    Kumeria T; Qu Z; Popat A; Altalhi T; Santos A
    Methods Mol Biol; 2019; 2054():185-198. PubMed ID: 31482457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease.
    Ichikawa HT; Williams LP; Segal BM
    J Immunol; 2002 Sep; 169(5):2781-7. PubMed ID: 12193753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles.
    Broos S; Sandin LC; Apel J; Tötterman TH; Akagi T; Akashi M; Borrebaeck CA; Ellmark P; Lindstedt M
    Biomaterials; 2012 Sep; 33(26):6230-9. PubMed ID: 22687756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD40 ligation in the presence of self-reactive CD8 T cells leads to severe immunopathology.
    Roth E; Schwartzkopff J; Pircher H
    J Immunol; 2002 May; 168(10):5124-9. PubMed ID: 11994466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of antigen to CD40 induces protective immune responses against tumors.
    Schjetne KW; Fredriksen AB; Bogen B
    J Immunol; 2007 Apr; 178(7):4169-76. PubMed ID: 17371973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence quenching in luminescent porous silicon nanoparticles for the detection of intracellular Cu2+.
    Xia B; Zhang W; Shi J; Xiao S
    Analyst; 2013 Jul; 138(13):3629-32. PubMed ID: 23676801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
    Ishihara J; Ishihara A; Potin L; Hosseinchi P; Fukunaga K; Damo M; Gajewski TF; Swartz MA; Hubbell JA
    Mol Cancer Ther; 2018 Nov; 17(11):2399-2411. PubMed ID: 30097487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of CD154:CD40 blocks generation of allograft immunity without affecting APC activation.
    Shepherd DM; Kerkvliet NI
    J Immunol; 1999 Sep; 163(5):2470-7. PubMed ID: 10452982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
    Carpenter EL; Mick R; Rüter J; Vonderheide RH
    J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
    Liu C; Lewis CM; Lou Y; Xu C; Peng W; Yang Y; Gelbard AH; Lizée G; Zhou D; Overwijk WW; Hwu P
    J Immunother; 2012 Apr; 35(3):276-82. PubMed ID: 22421945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-administration of CD40 agonistic antibody and antigen fails to overcome the induction of oral tolerance.
    Chung Y; Kim DH; Lee SH; Kang CY
    Immunology; 2004 Jan; 111(1):19-26. PubMed ID: 14678195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
    van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
    J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application.
    Filbert EL; Björck PK; Srivastava MK; Bahjat FR; Yang X
    Cancer Immunol Immunother; 2021 Jul; 70(7):1853-1865. PubMed ID: 33392713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
    Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
    Front Immunol; 2021; 12():786144. PubMed ID: 35095862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodegradable luminescent porous silicon nanoparticles for in vivo applications.
    Park JH; Gu L; von Maltzahn G; Ruoslahti E; Bhatia SN; Sailor MJ
    Nat Mater; 2009 Apr; 8(4):331-6. PubMed ID: 19234444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs.
    Taraban VY; Rowley TF; Al-Shamkhani A
    J Immunol; 2004 Dec; 173(11):6542-6. PubMed ID: 15557144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.